TGFB1 and neoplasm: Our in vivo results show that an anti-TGFβ antibody (1D11) significantly increased bone mineral density (BMD), trabecular thickness and bone volume, along with significant reduction in tumor burden and osteolytic bone damage in preclinical breast cancer bone metastasis models using both human and murine breast cancer cell lines.